Marlio Charles Mosseri Acquires 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 5,603 shares of the company’s stock in a transaction dated Friday, June 20th. The stock was bought at an average cost of $7.99 per share, with a total value of $44,767.97. Following the completion of the transaction, the insider now owns 2,981,806 shares in the company, valued at approximately $23,824,629.94. This trade represents a 0.19% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Wednesday, June 18th, Marlio Charles Mosseri purchased 28,043 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $8.05 per share, with a total value of $225,746.15.
• On Tuesday, June 17th, Marlio Charles Mosseri acquired 5,399 shares of Nuvectis Pharma stock. The shares were purchased at an average cost of $8.11 per share, for a total transaction of $43,785.89.
• On Monday, May 12th, Marlio Charles Mosseri bought 21,167 shares of Nuvectis Pharma stock. The shares were purchased at an average price of $8.11 per share, for a total transaction of $171,664.37.
• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was purchased at an average price of $8.65 per share, with a total value of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.59 per share, for a total transaction of $106,893.96.

Nuvectis Pharma Trading Down 3.0%

NASDAQ NVCT opened at $7.74 on Thursday. Nuvectis Pharma, Inc. has a 12 month low of $4.44 and a 12 month high of $11.80. The stock’s fifty day moving average price is $9.20 and its 200-day moving average price is $7.74. The stock has a market cap of $161.69 million, a P/E ratio of -6.85 and a beta of -0.16.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. As a group, analysts forecast that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in shares of Nuvectis Pharma during the fourth quarter valued at approximately $34,000. Blue Zone Wealth Advisors LLC bought a new stake in shares of Nuvectis Pharma in the 1st quarter worth $102,000. Baxter Bros Inc. increased its holdings in shares of Nuvectis Pharma by 20.0% in the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after purchasing an additional 2,500 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Nuvectis Pharma in the fourth quarter worth $103,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Nuvectis Pharma during the fourth quarter valued at $135,000. Institutional investors own 96.77% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $15.00 price objective (up previously from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th. Wall Street Zen raised shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. Laidlaw assumed coverage on shares of Nuvectis Pharma in a research note on Monday, March 17th. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Maxim Group started coverage on shares of Nuvectis Pharma in a report on Wednesday, April 2nd. They issued a “buy” rating and a $17.00 price objective on the stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.